KRT23 and idiopathic juvenile osteoporosis: Understanding more about the mechanism of CK2.3 as an antiresorptive agent will allow CK2.3 to be developed as a better and safer treatment to improve bone formation to combat diseases such as idiopathic juvenile osteoporosis, which hinders bone development in childhood.